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Abstract In the past 30 years there have been major
improvements in the care of children with chronic kidney
disease (CKD). However, most of the available epidemio-
logical data stem from end-stage renal disease (ESRD)
registries and information on the earlier stages of pediatric
CKD is still limited. The median reported incidence of renal
replacement therapy (RRT) in children aged 0–19 years
across the world in 2008 was 9 per million of the age-
related population (4–18 years). The prevalence of RRT in
2008 ranged from 18 to 100 per million of the age-related
population. Congenital disorders, including congenital
anomalies of the kidney and urinary tract (CAKUT) and
hereditary nephropathies, are responsible for about two
thirds of all cases of CKD in developed countries, while
acquired causes predominate in developing countries.
Children with congenital disorders experience a slower
progression of CKD than those with glomerulonephritis,
resulting in a lower proportion of CAKUT in the ESRD
population compared with less advanced stages of CKD.
Most children with ESRD start on dialysis and then receive
a transplant. While the survival rate of children with ERSD
has improved, it remains about 30 times lower than that of
healthy peers. Children now mainly die of cardiovascular
causes and infection rather than from renal failure.
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Introduction
Chronic kidney disease (CKD) refers to a condition related to
irreversible kidney damage that can further progress to end-
stage renal disease (ESRD). CKD is a major public health
problemworldwideandextensiveepidemiologicalresearchin
the adult population is available. In contrast, little is known
about the epidemiology of CKD in the pediatric population.
ESRD is a devastating disorder associated with excessive
mortality and cardiovascularmorbidity, and specificproblems
occur in children, such as impaired growth and psychosocial
adjustment, all of which severely impact upon the quality of
life [1–3]. A better understanding of the epidemiology of
CKD in children is essential in order to make a precise and
early diagnosis, identify preventable or reversible causes of
progression, predict prognosis, and aid the counseling of the
children and their families.
Definition of CKD
A possible reason for the limited information on the
epidemiology of CKD in the pediatric population is the
historical absence of a common definition and well-defined
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DOI 10.1007/s00467-011-1939-1classification of CKD. In 2002, the National Kidney Founda-
tion’s Kidney Disease Outcomes Quality Initiative (NKF-K/
DOQI) published a guideline on CKD, which included a
classification system for CKD severity, independent of cause,
and applicable to children [4]. Prior to the introduction of this
classification, various thresholds were used. For example, the
ItalKid Project, a prospective, population-based Italian study
on CKD epidemiology, and the North American Pediatric
Renal Trials and Collaborative Studies (NAPRTCS), defined
CKD as having a glomerular filtration rate (GFR) of below
75 ml/min/1.73 m
2 [5, 6]. Others based their definition on
serum creatinine levels themselves or on other thresholds of
GFR [7–9]. The K/DOQI classification system identifies five
stages of CKD based on the level of GFR. CKD is now
defined by a presence of kidney damage (for example, any
structural or functional abnormality involving pathological,
laboratory or imaging findings) for≥3m o n t h so raG F R <
60 ml/min/1.73 m
2 for≥3 months. The new classification
was widely adopted after its introduction; however, its
limitations and possible modifications have been a matter
of extensive discussion [10]. In children, the currently
available methods of estimating GFR are evolving, but a
proper assessment of renal function by estimated GFR
formulae remains challenging, particularly in the early stages
of kidney injury [11]. For example, the K/DOQI classifica-
tion does not apply to children under 2 years of age as GFR
increases from birth and reaches normal adult values by
2 years of age [4]. Furthermore, children born with major
structural anomalies will be considered to have CKD before
waiting 3 months for such a diagnosis.
Causes of CKD
Causes of CKD are very different in children from those in
adults. In the United States, the registry of the NAPRTCS
has collected data on the early stages of CKD in children
since 1994 [6]. The NAPRTCS Registry receives data from
pediatric nephrology centers on a voluntary basis and
includes more than 7,000 children aged under 21 years,
providing a large source of information on the etiology of
CKD in childhood [12]. In a recent NAPRTCS report
congenital causes, including congenital anomalies of the
kidney and urinary tract (CAKUT) (48%) and hereditary
nephropathies (10%), were the most common (Table 1).
Glomerulonephritis accounted for 14% of cases. The
distribution of causes varied with age. Whereas CAKUT
predominated in younger patients, glomerulonephritis was
the leading cause in children older than 12 years of age.
Causes of CKD vary across races, for example, focal
segmental glomerulosclerosis, the main cause of glomerular
disease, was three times more common in blacks than in
whites (19 vs 6%) and especially among black adolescents
(35%) [12]. A fairly similar distribution of causes of CKD
has been reported in Europe by the Italian and the Belgian
registries [5, 13]. The proportions of CAKUT (58–59%)
and hereditary nephropathy (15–19%) were slightly higher,
while the proportion of glomerulonephritis was lower (5–
7%) than in the NAPRTCS database, possibly because of
the difference in racial distribution.
In view of a dearth of national registries and surveys,
estimating the causes of CKD in children in low and middle
income countries is difficult. In Turkey and other countries
in the Middle East, CAKUT is the leading cause of CKD
(47–62%) with a clear predominance of uropathies over
hypodysplasia followed by hereditary nephropathies (17 to
30%) [9, 14–16]. Of note, neuropathic bladder remained an
important cause of CKD in Turkey (15%), while it
accounted for about 4% in Italy and Belgium. These
figures may reflect a delay in appropriate urological
diagnosis and treatment. In addition, the higher proportion
of genetic diseases found in the Middle East than in Europe
may be explained by a higher prevalence of consanguine-
ous marriages. Chronic glomerulonephritis is the main
reported cause of CKD in various studies from India,
Southeast Asia, Latin America and Caribbean area and sub-
Saharan Africa, with a prevalence ranging from 30 to
almost 60% [17–25]. Such high proportions of glomerulo-
nephritis may be related to high prevalence of bacterial,
viral, and parasitic infections that commonly affect the
kidneys in developing countries, as well as a different age
distribution in these reports where patients are referred in
the later stages of CKD.
In the United States Renal Data System (URDS)
Registry, congenital disorders (CAKUT and hereditary
nephropathies) were the most common etiologies in the
youngest ESRD group, whereas the proportion of acquired
diseases increased progressively with age [26]. Overall,
CAKUT are the main causes, accounting for 34–43% of
pediatric ESRD cases in Europe, Japan, Australia, and New
Zealand (Table 1)[ 27–30]. In 2008, the proportion of
ESRD caused by glomerulonephritis was lower in Europe
according to the ESPN/ERA-EDTA registry (15%) com-
pared with a Japanese study (22%) and the Australia and
New Zealand Dialysis and Transplant Registry (ANZDATA;
29%). The ANZDATA Registry showed a decline in
glomerulonephritis as a cause of ESRD over time.
However, this may be due to the age distribution of
patients, with fewer young patients being treated for ESRD
at that time. There was also a decline in the proportion of
ESRD caused by reflux nephropathy, while obstructive
uropathy and hypodysplasia increased [31]. This trend may
be explained by a change in reporting the primary
diagnosis, since the combined proportion of hypodysplasia
and reflux nephropathy has remained stable over the past
30 years.
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While screening and surveillance of CKD in adults, either
population-based or targeted at-risk populations, have
become important parts of CKD prevention strategies
worldwide, the benefit of such programs in children is
much more controversial [32]. Tests used for CKD
screening in children are usually limited to urinary dipstick
protein instead of urine albumin/creatinine ratio or
creatinine-based calculation of estimated GFR, as recom-
mended for adults. However, there is a large variation in the
methods used and approaches taken by different countries,
and the findings have shown poor reproducibility (Table S1
and references in ESM).
Mass screening programs to detect CKD in children
have been well established for many years in several Asian
countries, such as Japan, Taiwan, and Korea [33–35].
Conversely, screening programs have not been adopted in
Europe, but urine screening dipsticks have routinely been
used in healthy children for decades in the United States. In
2000, the recommendations from the American Academy
of Pediatrics were to screen urine in two groups: preschool
children and adolescents [36]. This policy was revised in
2007; thus, this practice is no longer recommended [37].
Although a decrease in the incidence of ESRD has been
observed in Japan and Taiwan, there is only limited
evidence that early detection of kidney injury in children
may lead to effective interventions to slow the progression
of CKD and to further reduce the risk of developing ESRD
[32]. Furthermore, recent studies suggest that a urine
dipstick is not cost-effective in screening children [38].
Demographics of CKD
There is limited information on the epidemiology of the
early stages of CKD in the pediatric population as it is often
asymptomatic and therefore under-diagnosed and under-
reported. Although some pediatric CKD registries using K/
DOQI classification are beginning to emerge, only a few
reports on the epidemiology of CKD stages 2 to 5 in
children are available, and even less is known about low-
income countries. For these countries, data is mostly
obtained from reports of major tertiary care referral centers,
but the validity of this data is variable.
Europe
Several pediatric nephrology societies from European
countries have provided data on the early stages of CKD
(Table 2)[ 5, 7, 8, 13, 14, 39]. Even though age categories
and the definition of CKD differed among countries, the
incidence in Europe was fairly consistent, being around 11–
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366 Pediatr Nephrol (2012) 27:363–37312 per million of the age-related population (pmarp) for
CKD stages 3–5, and 8 pmarp for CKD stages 4–5. While
an increase in incidence since the 1970s was seen in
France, this was not shown in Sweden [8, 40]. Prevalence
ranged from about 55–60 to 70–75 pmarp in Spain and
Italy, depending on the clinical definition of CKD that was
used in each study. Another consistent finding was the
predominance of the male gender (male/female ratio
ranging from 1.3 to 2.0) reflecting in particular the higher
incidence of CAKUT in boys than in girls.
Latin America
InChile,anationalsurveyofpediatricnephrologistsestimated
an incidence of CKD (GFR<30 ml/min/1.73 m
2)i nc h i l d r e n
aged less than 18 years of 5.7 pmarp and a prevalence of
42.5 pmarp in 1996 [41]. Among these patients, half were on
conservative treatment and the others were on renal
replacement therapy (RRT). A study on the epidemiology
of CKD conducted in several Latin American countries
(Argentina, Brazil, Chile, Colombia, Mexico, Uruguay, and
Venezuela) showed a wide variation in incidence that ranged
from 2.8 to 15.8 new cases pmarp [42].
Middle East and South East Asia
The referral center for pediatric kidney diseases in Kuwait
provided data on children aged 0–15 years with a GFR<
50 ml/min/1.73 m
2 [9]. The mean incidence was found to be
as high as 38 pmarp, whereas the prevalence increased from
188 in 1996 to a rate as high as 329 pmarp in 2003. The
marked difference in incidence between Kuwaiti children
and non-Kuwaiti residents suggested a role of genetic factors
[9]. An incidence of 11 pmarp and a prevalence of 51 pmarp
have been reported in Jordanian children [16]. Two reports
from Vietnam have suggested an annual incidence of
hospitalization for CKD of around 5 pmarp, and most of
the patients had already reached ESRD [19, 20].
Sub-Saharan Africa
Single-center studies from sub-Saharan Africa have shown
a very low incidence of CKD, estimated at 3 pmarp in
Nigeria, which did not offer pediatric RRT, and 1–2 pmarp
in South Africa [23, 24].
Demographics of ESRD
Incidence and prevalence of ESRD
There are marked variations in the incidence and prevalence
of ESRD in the pediatric population across countries.
Approximately 80% of RRT patients worldwide live in
Europe, Japan or North America, where all children with
ESRD have access to RRT. By contrast, limited health care
resources and lack of trained personnel in developing
countries result in rationing of or even not offering RRT.
In 2008, the medianincidence ofRRTin children aged less
than 20 years was around 9 pmarp, varying from less than 4
(Russia)to18pmarp (NewZealand;Fig.1). The incidence of
RRT was 9.5 pmarp among 11 western European countries
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Fig. 1 Incidence of renal replacement therapy (RRT) in children in
2008 by country. The light bars correspond to the incidence in
children aged 0–14 years, the sum of the light and the dark bars
corresponds to the incidence in children aged 0–19 years. *France 16
out of 26 regions, Italy 13 out of 20 regions, Spain 4 out of 18 regions
in the 15- to 19-year-old age group
Pediatr Nephrol (2012) 27:363–373 367and in Australia compared with 15.5 in the United States [26,
27, 43]. As a comparison, the incidence of RRT in adults
varied from around 100–150 in Europe and Australia to
300–350 in Japan and the United States in 2008 [26].
In every registry, a higher incidence was found in
adolescents. The incidence was twice as high in the United
States as in western Europe in the 15- to 19-year age group
(30.6 vs 15.3) and was also higher in the 0- to 14-year age
group (10.5 vs 6.5 in western Europe). This difference
might be partly explained by the timing of initiation of RRT.
Indeed, RRT was started at a median GFR of 10.4 ml/min/
1.73 m
2 in European children, whereas mean GFR ranged
from 11.3 to 13.6 ml/min/1.73 m
2 in the United States [44,
45]. In Japan, the incidence of pediatric RRT (4.3 pmarp)
was much lower than in other high-income countries (Dr
Hattori, personal communication, used with permisson),
even though Japan has one of the highest incidence rates of
ESRD in adults. The incidence in Malaysia was comparable
to that of Europe, suggesting good access to RRT in this
country, which has a publically funded dialysis program
[46]. In previous reports from countries offering RRT,
incidence rates of RRT varied from 6.5 pmarp in Brazil in
the late 1980s to 17 pmarp in Kuwait in the period 1995–
2002 [47, 48]. In developing countries where RRT is
unaffordable for all but the very wealthy, incidence rates are
extremely low (< 1 pmarp in Bangladesh and Nepal).
The prevalence of children with RRT in 2008 was
around 65 pmarp in Australia, Canada, Malaysia, and
western Europe, with the exception of Finland where a high
incidence of ESRD in infants due to congenital nephrotic
syndrome of the Finnish type led to a greater prevalence of
RRT (Fig. 2). The prevalence was higher in the United
States (85 pmarp), whilst Japan had a lower prevalence (34
pmarp). A recent survey conducted in the most populated
Brazilian State showed a prevalence of 23 pmarp in
children less than 18 years of age (Dr Koch Nogueira,
personal communication, used with permisson). Incidence
and prevalence also differ by race. African–American
children had an almost two-fold greater incidence of ESRD
compared with white children [26], while in Australia and
New Zealand, kidney disease is more common in Maori,
Pacific Island, and indigenous Australian people than in
non-indigenous people, although the difference in incidence
of ESRD is mainly among those over the age of 15 years
[49]. In the UK, the prevalence and the incidence of RRT in
children from the south Asian population in 2008 were 2.5
and 1.5 times greater than that of the white population aged
0–15 years [29].
Changing trends
IntheUnitedStates,theadjustedannualincidenceofESRDin
the pediatric population rose slowly during the 1980s, and
then increased marginally from 14 to 15 pmarp between 1990
and 2008 [26]. The adjusted prevalence increased from 60 to
85 in the same period. The incidence of ESRD in children
aged less than 18 years from Australia and New Zealand has
remained constant at about 8 pmarp over the past 25 years,
while the prevalence of RRT increased from approximately
30 to 50 pmarp [31]. A report from the EDTA registry on
patients aged 0–19 years starting RRT between 1980 and
2000 in 12 western European countries showed that the
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Fig. 2 Prevalence of RRT in children on 31 December 2008 by
country. The light bars correspond to the prevalence in children aged
0–14 years, the sum of the light and the dark bars corresponds to the
prevalence in children aged 0–19 years. *France 16 out of 26 regions,
Italy 13 out of 20 regions, Spain 4 out of 18 regions in the 15- 19-
year-old age group;
†State of Sao Paulo
368 Pediatr Nephrol (2012) 27:363–373incidence of RRT rose from 7 pmarp in 1980–1984 to 10
pmarp in 1985–1989, and remained stable thereafter [50].
The prevalence increased from 22.9 pmarp in 1980 to 62
pmarp in 2000. The increase in prevalence is explained by
improved survival and treatment of younger children.
Treatment modalities
Countries vary considerably in the distribution of initial
treatment modality [50]. Some countries, like Japan or
Turkey, preferentially use peritoneal dialysis (PD) [27, 51],
but in most registries about half of children younger than
20 years of age commenced RRT with hemodialysis (HD;
Table 3). Initial RRT varies with age since PD is the
preferred choice in children aged 0–14 years in Europe and
the United States, whereas three-quarters of children aged
15–19 years start with HD [26, 43]. This may reflect the
management of many adolescents in adult units where HD
is more likely to be proposed than in pediatric units.
Registry data have shown that 65–80% of children and
adolescents on RRT programs have a kidney transplant
(Table 3), with the exception of Japan where the transplan-
tation rate was very low in data from 1998.
In developing countries, dialysis is often not offered.
Survival therefore depends on the development of locally
appropriate transplant programs. The lack of deceased
donors might lead to pressure on relatives to become living
donors and a trade in paid organ donation.
Mortality and morbidity
At the start of RRT programs in the 1960s, the case-fatality
rate was 11.0 per 100 patient years [52]. Since then, there has
been much improvement, now showing a stable case-fatality
rate of 1.3–1.8 per 100 patient years in the past 15 years
[50, 52]. Survival is similar throughout the developed
world [52–54], but still the mortality rate in children with
RRT is about 30 times higher than in their healthy peers [52,
53]. Infants with severe renal disease are at higher risk of
death in the first 2 years of life, but outcomes thereafter are
comparable to those of older children [55]. Transplant
patients consistently have up to a 4-fold survival benefit
compared with dialysis patients [45, 52]. Among young
adults who started RRT during childhood, the average life
expectancy was 63 years for those with a functioning graft
compared with 38 years for those remaining on dialysis [56].
Other risk factors for a higher mortality include the presence
of co-morbidities, and long standing hypertension [52, 53].
The two major causes of mortality in pediatric RRT are
cardiovascular disease and infections, accounting for 30–
40% and 20–50% of deaths respectively [12, 45, 52, 53].
Also, the burden of morbidity from cardiovascular disease
and infections is high, as, for example, infections caused 600
admissions per 1,000 patient years and cardiovascular disease
350 admissions per 1,000 patient years in the first month of
starting dialysis, according to the most recent USRDS report
[26]. In transplant patients, infection has overtaken acute
rejection as the primary cause of hospital admissions [57].
Progression of CKD
The progression of CKD is variable and depends on the
underlying disease, the severity of the initial injury, and the
presence of additional risk factors. Data from the NAPRTCS
on more than 4,000 children with CKD stages 2–4s h o w e da
progression rate to ESRD of 17% at 1 year and 39% at 3 years
followingregistration,withamediantimetoESRDof4.5years
[58]. The rate of progression was inversely proportional to
baseline GFR. In the ItalKid project, the incidence of RRT
was 7.3 per year per 100 patients with CKD, and the risk of
ESRD was 68% by the age of 20 years [5].
Table 3 Comparison of RRT modalities within registries in children
*
Registry (number of countries) Age (years) Initial treatment modality (%) Prevalent treatment modality (%)
HD PD Transplantation HD PD Transplantation
ANZDATA (2) 0–19 45 39 16 12 15 73
ERA-EDTA (11) 0–19 44 35 21 13 7 80
ESPN/ERA-EDTA (31) 0–14 36 49 15 14 21 65
USRDS (1) 0–19 52 31 17 17 11 71
0–14 35 46 19 15 11 74
CORR/Canada (1) 0–19 52 30 18 9 13 78
Japan (1) 0–18 30 69 1 17 42 41
USRDS, US Renal Data System; CORR, Canadian Organ Replacement Register
*Prevalence at 31 December 2008, except data from Japan at 1 January 1998, incidence reported from data in 2008 (ESPN/ERA-EDTA and
USRDS), 2003–2008 (ANZDATA), 2007–2008 (ERA-EDTA), 2007–2009 (CORR), and 1998 (Japan)
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Children with congenital disorders experience a slower
progression of CKD than those with glomerulonephritis,
resulting in a relatively decreased proportion of hypodys-
plasia and uropathies in the RRT population compared with
less advanced stages of CKD. Also, the rate of progression
of CKD is usually greater during puberty [5, 59]. Potential
mechanisms include a higher blood pressure, imbalance
between residual nephron mass and filtration demands
during this period of rapid change in body size, as well as
altered endocrine physiology. A low birth weight is
associated with a lower number of nephrons, which might
predispose to hypertension and CKD in later life [60].
Although it has been clearly established that many ethnic
minorities suffer a greater incidence of ESRD compared
with whites [26, 29], the evidence to date does not show
ethnic differences in the rates of progression of CKD in
children. Possible confounders, such as unequal access to
care, are difficult to assess.
Finally, genetic predisposition may influence the rate of
progression of CKD. Several recent genome-wide associa-
tion studies have identified genetic loci that relate to CKD
susceptibility and progression in adults [61].
Modifiable progression factors
Hypertension and proteinuria are the most important indepen-
dentriskfactorsforrenaldiseaseprogressioninbothadultand
pediatric CKD [62–64]. Hypertension is present in approx-
imately 50% of children with CKD and masked hypertension
(i.e., normal casual but elevated ambulatory blood pressure)
is often present [65, 66]. The ESCAPE study group showed
that strict blood pressure control under the 50th percentile
slows pediatric CKD progression during 5 years’ follow-up
[67]. In the ESCAPE trial, the initial antiproteinuric response
to angiotensin-converting enzyme inhibitor therapy was
predictive of renal survival, despite the occurrence of a
proteinuria rebound in half of the patients [67]. There is clear
evidence in adults that obesity is associated with an increased
risk of development and progression of kidney disease [68].
A similar association has also been documented in obese
children, even though there is a lack of large and long-term
follow-up studies [69]. Other factors potentially involved in
the progression of CKD have been addressed in adult
patients, including metabolic acidosis, anemia, altered
calcium-phosphate homeostasis, chronic inflammation, and
metabolic factors, such as diabetes, hyperuricemia, dyslipi-
demia, and smoking [70–75]. Pediatric retrospective data
suggest that many factors such as anemia, hypoalbuminemia,
hyperphosphatemia, and hypocalcemia might be associated
with the rate of CKD progression, implying potential
measures to preserve renal function [59, 76]. However, these
data require confirmation from ongoing prospective cohort
studies on pediatric CKD [77, 78].
Conclusion
Recent years have shown a tremendous increase in the
amount of available data on CKD and ESRD in children.
Nevertheless, there are still only limited data on the earlier
stages of CKD. As numbers of patients are small, more
research is needed to improve the understanding of the
differences in incidence between countries, causes and
progression of CKD in order to prevent renal failure, as
well as improved quality of care among patients with
ESRD. To allow for international comparisons in future
studies, we recommend using the K/DOQI guidelines to
define the stages of CKD and publishing data for similar
age groups (by showing separate data for children aged 0–
14 years and what is available above 15 years of age).
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Questions (Answers appear following the reference list)
1. Which of the following statements regarding CKD is false?
a) The KDOQI guidelines define CKD as a GFR<
50 ml/min/1.73 m
2
b) GFR increases from birth and reaches adult values
by 2 years of age
c) CAKUT is the major cause of CKD worldwide,
although the proportion of glomerulonephritis in
developing countries ishigherdue to infectiouscauses
d) There are few population-based studies in the early
stages of CKD as it is often asymptomatic
2. Which of the following statements regarding screening
in children is true?
a) Screening is currently recommended in children in
the USA by the American Academy of Pediatrics
370 Pediatr Nephrol (2012) 27:363–373b) Screening has been proven to reduce the develop-
ment of ESRD
c) Screening mainly employs dipsticks in children, as
opposed to calculating GFR in adults
d) Urine dipstick testing is a cost-effective strategy for
detecting CKD
3. Which of the following statements regarding ESRD is
false?
a) Prevalence of ESRD is increasing owing to better
overall survival and increased uptake of younger
children and infants into RRT programs
b) The prevalence of RRT in 2008 in Australia,
Canada, and western Europe (except Finland) is
around 65 pmarp
c) Access to ESRD programs is highly dependent on
socio-economic factors and as such, is limited in
poorly developed countries
d) Incidence of ESRD varies depending on age and
ethnic group
e) Themajorityofchildrenaretransplantedpre-emptively
4. Which of the following regarding mortality and
morbidity is false?
a) The mortality rate has remained relatively un-
changed in the last 15 years and is about 30 times
higher than in healthy peers
b) Children on dialysis have a higher mortality rate
compared with transplanted patients
c) Rejection is the main cause of admission in trans-
planted children
d) 20–40% of deaths in RRT are cardiovascular-related
5. Which of the following statements regarding CKD
progression is not true?
a) Hypertension is a major risk factor for CKD
progression
b) Hyperphosphatemia is an independent risk factor
for CKD progression, as has been shown in
prospective studies
c) There is evidence that the progression of CKD can
be slowed by pharmacological intervention
d) The rate of CKD progression is inversely propor-
tional to baseline GFR
e) Children with congenital disorders experience a
slower progression of CKD than those with
glomerulonephritis
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